All In Biotech

Drug Trial Radar · NCT02847637

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients Without Inhibitors

Last checked: Nov 20, 2026Latest source record: Nov 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

152

Actual

Start

Sep 27, 2016

Primary completion

Sep 15, 2017

Study completion May 12, 2022

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
Jul 28, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older. The study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emphasis on efficacy, safety, and pharmacokinetics.

Conditions

  • Hemophilia A

Interventions

  • EmicizumabDrug

    Participants received emicizumab prophylaxis subcutaneously at the specified dose for each arm. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant had the option to choose a preferred emicizumab dosing regimen among those permitted (i.e., emicizumab 1.5 mg/kg once every week \[QW\], 3 mg/kg once every 2 weeks \[Q2W\], or 6 mg/kg once every 4 weeks \[Q4W\]) and continue on that dosing regimen until discontinuation from the study.

  • Factor VIII (FVIII)Drug

    FVIII was allowed to treat bleeds on an episodic basis, per the local prescribing information. Specific dosages of FVIII were not mandated in the study. Breakthrough bleeds were to be treated with the lowest FVIII dose expected to achieve hemostasis, which may have been lower than the participant's prior FVIII dose. To avoid bleeds before adequate emicizumab level is reached, patients in Arm D continued their regular FVIII prophylaxis until the second emicizumab loading dose. Concomitant routine FVIII prophylaxis was not permissible otherwise during the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Bleeding Rate (ABR) for Treated BleedsTime frame: From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)

Locations

39 sites in 14 countries. Site status is shown where the registry gives one.

  • Santa Monica Oncology Center

    Santa Monica, California

  • Georgetown Uni Medical Center; Lombardi Cancer Center

    Washington D.C., District of Columbia

  • University of Florida

    Gainesville, Florida

  • Winship Cancer Institute

    Atlanta, Georgia

  • Dana-Farber Cancer Institute; Brigham and Women's Cancer Center

    Boston, Massachusetts

  • Children's Hospital of Michigan; Pediatrics

    Detroit, Michigan

  • Cornell Univ Medical College; Hematology-Oncolog

    New York, New York

  • Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia

    Seattle, Washington

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit

    Melbourne, Victoria, Australia

  • The Perth Blood Institute

    Nedlands, Western Australia, Australia

  • ICIC

    San José, Costa Rica

  • Hopital Cardio-vasculaire Louis Pradel; Hemostase clinique

    Bron, France

  • CH de Bicetre; Centre de Traitement d' Hemophilie

    Le Kremlin-Bicêtre, France

  • Groupe Hospitalier Necker Enfants Malades

    Paris, France

  • Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin

    Bonn, Germany

  • St James's Hospital

    Dublin, Ireland

  • IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi "Angelo Bianchi e Bonomi"

    Milan, Lombardy, Italy

  • AOU Careggi; SOD Malattie Emorragiche

    Florence, Tuscany, Italy

  • Nagoya University Hospital

    Aichi, Japan

  • St. Marianna University Hospital

    Kanagawa, Japan

  • Sendai Medical Center

    Miyagi, Japan

  • Nara Medical University Hospital

    Nara, Japan

  • NHO Osaka National Hospital

    Osaka, Japan

  • Tokyo Medical University Hospital

    Tokyo, Japan

  • Ogikubo Hospital

    Tokyo, Japan

  • Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii

    Gdansk, Poland

  • SPSK Nr1 Klinika Hematoo&Transpl.Szpiku

    Lublin, Poland

  • ALVAMED Lekarskie Gabinety Specjalistyczne

    Poznan, Poland

  • Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych

    Warsaw, Poland

  • Charlotte Maxeke Johannesburg Hospital; Haemophilia Comprehensive Care Center

    Johannesburg, South Africa

  • Severance Hospital

    Seoul, South Korea

  • Hospital Universitario la Paz; Servicio de Hematologia

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio; Servicio de Hematologia

    Seville, Spain

  • Changhua Christian Hospital

    Chang-hua, Taiwan

  • Taichung Veterans General Hospital

    Taichung, Taiwan

  • Taipei Medical University Hospital

    Taipei, Taiwan

  • Cardiff and Vale NHS Trust

    Cardiff, United Kingdom

  • Royal Free Hospital; Haemophilia Centre

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.